J45.20 — Mild Intermittent Asthma
Denied31F · medication — Biologic therapy (omalizumab)
Insurer Rationale
Biologic therapy is reserved for severe refractory asthma after standard step-up therapy has failed. The requested treatment does not meet criteria.
Reasoning Chain
This denial is consistent with stepwise asthma care. The patient is still near the entry point of the ladder, so moving directly to omalizumab skips multiple safer and evidence-backed controller steps.
Reasoning Chain
Findings
Intermittent wheeze, Symptoms under twice weekly, No recent hospitalisations, Night waking rare
Diagnosis
Asthma (mild intermittent pattern)
Assessment
GINA step review — Severe refractory criteria are not met because baseline controller therapy has not been tried and disease burden is low.
Guideline action
Begin standard inhaled controller therapy before biologic escalation
Verdict
Denial is clinically correct because omalizumab belongs far later in the asthma treatment pathway.
Clinical Evidence
GINA Global Strategy for Asthma Management (2025)
Stepwise treatment
Biologics are reserved for severe asthma after optimisation of inhaled controller therapy.
NICE Asthma Guideline
Pharmacological treatment pathway
Escalation follows inhaled controller steps before specialist biologic therapy is considered.